Given the clinical significance of the ERBB family in breast cancer and the clinical activity of neratinib, we conducted a preclinical study to identify kinase and pathway inhibitors that may enhance the anti-tumor activity of neratinib not only in HER2+ breast cancer but also in TNBC. This evidence concerns the gene EGFR and breast cancer.